CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV) announced today that Dr. Daniel Carr, CEO and CMO, and members of Javelin’s senior management will host a call on three recent milestones as well as progress in the clinical development of PMI-150 (intranasal ketamine). The call will be held tomorrow June 28, 2007 at 8:30 a.m. EDT.
